PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations
Background Although immune checkpoint inhibitors have revolutionized cancer treatment, clinical benefit with this class of agents has been limited to a subset of patients. Hence, more effective means to target tumor cells that express immune checkpoint molecules should be developed. For the first ti...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-05-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/1/e000450.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850062679167729664 |
|---|---|
| author | Jeffrey Schlom James W Hodge Clint T. Allen Shahrooz Rabizadeh Patrick Soon-Shiong John H. Lee Renee N. Donahue Kristen Solocinski Michelle R Padget Kellsye P Fabian Yvette Robbins |
| author_facet | Jeffrey Schlom James W Hodge Clint T. Allen Shahrooz Rabizadeh Patrick Soon-Shiong John H. Lee Renee N. Donahue Kristen Solocinski Michelle R Padget Kellsye P Fabian Yvette Robbins |
| author_sort | Jeffrey Schlom |
| collection | DOAJ |
| description | Background Although immune checkpoint inhibitors have revolutionized cancer treatment, clinical benefit with this class of agents has been limited to a subset of patients. Hence, more effective means to target tumor cells that express immune checkpoint molecules should be developed. For the first time, we report a novel natural killer (NK) cell line, programmed death-ligand 1 (PD-L1) targeting high-affinity natural killer (t-haNK), which was derived from NK-92 and was engineered to express high-affinity CD16, endoplasmic reticulum-retained interleukin (IL)-2, and a PD-L1-specific chimeric antigen receptor (CAR). We show that PD-L1 t-haNK cells also retained the expression of native NK receptors and carried a high content of granzyme and perforin granules.Methods NanoString, flow cytometry, and immunofluorescence analyses were performed to characterize the phenotype of irradiated PD-L1 t-haNK cells. In vitro PD-L1 t-haNK cell activity against cancer cell lines and human peripheral blood mononuclear cells (PBMCs) was determined via flow-based and 111In-release killing assays. The antitumor effect of PD-L1 t-haNK cells in vivo was investigated using MDA-MB-231, H460, and HTB1 xenograft models in NOD-scid IL2Rgammanull (NSG) mice. Additionally, the antitumor effect of PD-L1 t-haNK cells, in combination with anti-PD-1 and N-803, an IL-15 superagonist, was evaluated using mouse oral cancer 1 syngeneic model in C57BL/6 mice.Results We show that PD-L1 t-haNK cells expressed PD-L1-targeting CAR and CD16, retained the expression of native NK receptors, and carried a high content of granzyme and perforin granules. In vitro, we demonstrate the ability of irradiated PD-L1 t-haNK cells to lyse 20 of the 20 human cancer cell lines tested, including triple negative breast cancer (TNBC) and lung, urogenital, and gastric cancer cells. The cytotoxicity of PD-L1 t-haNK cells was correlated to the PD-L1 expression of the tumor targets and can be improved by pretreating the targets with interferon (IFN)-γ. In vivo, irradiated PD-L1 t-haNK cells inhibited the growth of engrafted TNBC and lung and bladder tumors in NSG mice. The combination of PD-L1 t-haNK cells with N-803 and anti-PD-1 antibody resulted in superior tumor growth control of engrafted oral cavity squamous carcinoma tumors in C57BL/6 mice. In addition, when cocultured with human PBMCs, PD-L1 t-haNK cells preferentially lysed the myeloid-derived suppressor cell population but not other immune cell types.Conclusion These studies demonstrate the antitumor efficacy of PD-L1 t-haNK cells and provide a rationale for the potential use of these cells in clinical studies. |
| format | Article |
| id | doaj-art-2cdc94ab811b4ee3a4c9aeb0ebba45c0 |
| institution | DOAJ |
| issn | 2051-1426 |
| language | English |
| publishDate | 2020-05-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-2cdc94ab811b4ee3a4c9aeb0ebba45c02025-08-20T02:49:50ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-05-018110.1136/jitc-2019-000450PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populationsJeffrey Schlom0James W Hodge1Clint T. Allen2Shahrooz Rabizadeh3Patrick Soon-Shiong4John H. Lee5Renee N. Donahue6Kristen Solocinski7Michelle R Padget8Kellsye P Fabian9Yvette Robbins10Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA1 Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA2 Section on Translational Tumor Immunology, National Institute on Deafness and Other Communication Disorders, Bethesda, Maryland, USASagittarius Bio, Inc., Thousand Oaks, CA, USA2 NantOmics, Culver City, California, USA3 ImmunityBio, Santa Cruz, California, USA1 Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA1 Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USACenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USACenter for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USASection on Translational Tumor Immunology, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD, USABackground Although immune checkpoint inhibitors have revolutionized cancer treatment, clinical benefit with this class of agents has been limited to a subset of patients. Hence, more effective means to target tumor cells that express immune checkpoint molecules should be developed. For the first time, we report a novel natural killer (NK) cell line, programmed death-ligand 1 (PD-L1) targeting high-affinity natural killer (t-haNK), which was derived from NK-92 and was engineered to express high-affinity CD16, endoplasmic reticulum-retained interleukin (IL)-2, and a PD-L1-specific chimeric antigen receptor (CAR). We show that PD-L1 t-haNK cells also retained the expression of native NK receptors and carried a high content of granzyme and perforin granules.Methods NanoString, flow cytometry, and immunofluorescence analyses were performed to characterize the phenotype of irradiated PD-L1 t-haNK cells. In vitro PD-L1 t-haNK cell activity against cancer cell lines and human peripheral blood mononuclear cells (PBMCs) was determined via flow-based and 111In-release killing assays. The antitumor effect of PD-L1 t-haNK cells in vivo was investigated using MDA-MB-231, H460, and HTB1 xenograft models in NOD-scid IL2Rgammanull (NSG) mice. Additionally, the antitumor effect of PD-L1 t-haNK cells, in combination with anti-PD-1 and N-803, an IL-15 superagonist, was evaluated using mouse oral cancer 1 syngeneic model in C57BL/6 mice.Results We show that PD-L1 t-haNK cells expressed PD-L1-targeting CAR and CD16, retained the expression of native NK receptors, and carried a high content of granzyme and perforin granules. In vitro, we demonstrate the ability of irradiated PD-L1 t-haNK cells to lyse 20 of the 20 human cancer cell lines tested, including triple negative breast cancer (TNBC) and lung, urogenital, and gastric cancer cells. The cytotoxicity of PD-L1 t-haNK cells was correlated to the PD-L1 expression of the tumor targets and can be improved by pretreating the targets with interferon (IFN)-γ. In vivo, irradiated PD-L1 t-haNK cells inhibited the growth of engrafted TNBC and lung and bladder tumors in NSG mice. The combination of PD-L1 t-haNK cells with N-803 and anti-PD-1 antibody resulted in superior tumor growth control of engrafted oral cavity squamous carcinoma tumors in C57BL/6 mice. In addition, when cocultured with human PBMCs, PD-L1 t-haNK cells preferentially lysed the myeloid-derived suppressor cell population but not other immune cell types.Conclusion These studies demonstrate the antitumor efficacy of PD-L1 t-haNK cells and provide a rationale for the potential use of these cells in clinical studies.https://jitc.bmj.com/content/8/1/e000450.full |
| spellingShingle | Jeffrey Schlom James W Hodge Clint T. Allen Shahrooz Rabizadeh Patrick Soon-Shiong John H. Lee Renee N. Donahue Kristen Solocinski Michelle R Padget Kellsye P Fabian Yvette Robbins PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations Journal for ImmunoTherapy of Cancer |
| title | PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations |
| title_full | PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations |
| title_fullStr | PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations |
| title_full_unstemmed | PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations |
| title_short | PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations |
| title_sort | pd l1 targeting high affinity nk t hank cells induce direct antitumor effects and target suppressive mdsc populations |
| url | https://jitc.bmj.com/content/8/1/e000450.full |
| work_keys_str_mv | AT jeffreyschlom pdl1targetinghighaffinitynkthankcellsinducedirectantitumoreffectsandtargetsuppressivemdscpopulations AT jameswhodge pdl1targetinghighaffinitynkthankcellsinducedirectantitumoreffectsandtargetsuppressivemdscpopulations AT clinttallen pdl1targetinghighaffinitynkthankcellsinducedirectantitumoreffectsandtargetsuppressivemdscpopulations AT shahroozrabizadeh pdl1targetinghighaffinitynkthankcellsinducedirectantitumoreffectsandtargetsuppressivemdscpopulations AT patricksoonshiong pdl1targetinghighaffinitynkthankcellsinducedirectantitumoreffectsandtargetsuppressivemdscpopulations AT johnhlee pdl1targetinghighaffinitynkthankcellsinducedirectantitumoreffectsandtargetsuppressivemdscpopulations AT reneendonahue pdl1targetinghighaffinitynkthankcellsinducedirectantitumoreffectsandtargetsuppressivemdscpopulations AT kristensolocinski pdl1targetinghighaffinitynkthankcellsinducedirectantitumoreffectsandtargetsuppressivemdscpopulations AT michellerpadget pdl1targetinghighaffinitynkthankcellsinducedirectantitumoreffectsandtargetsuppressivemdscpopulations AT kellsyepfabian pdl1targetinghighaffinitynkthankcellsinducedirectantitumoreffectsandtargetsuppressivemdscpopulations AT yvetterobbins pdl1targetinghighaffinitynkthankcellsinducedirectantitumoreffectsandtargetsuppressivemdscpopulations |